BCM
IRD

BIOS Capital Management’s Opus Genetics IRD Stock Holding History

BIOS Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Hold
3,683,429
– – 36.33% 2
2026
Q1 		$16.8M Hold
3,683,429
– – 31.7% 2
2025
Q4 		$7.4M Hold
3,683,429
– – 8.96% 3
2025
Q3 		$6.59M Hold
3,683,429
– – 7.42% 3
2025
Q2 		$3.46M Buy
3,683,429
+2,688,180
+270% +$2.49M 4.77% 2
2025
Q1 		$977K Hold
995,249
– – 1.23% 6
2024
Q4 		$1.18M Buy
+995,249
New +$1.14M 1.26% 6

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

BIOS Capital Management's IRD Position: Q2 2026 in Review

BIOS Capital Management held its Opus Genetics (IRD) position steady in Q2 2026 at 3,683,429 shares worth $15.1M. The position accounts for 36.33% of the portfolio, ranked #2.

BIOS Capital Management first reported a position in IRD in Q4 2024 and has held it in 7 quarters since. The position peaked at $16.8M in Q1 2026. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • BIOS Capital Management held 3,683,429 shares of Opus Genetics worth $15.1M as of Q2 2026.
  • BIOS Capital Management left its Opus Genetics share count unchanged in Q2 2026.
  • Opus Genetics made up 36.33% of BIOS Capital Management's portfolio in Q2 2026, its #2 holding.
  • BIOS Capital Management first reported a position in Opus Genetics in Q4 2024 and has held it in 7 quarters since.
  • BIOS Capital Management's Opus Genetics position peaked at $16.8M in Q1 2026.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on BIOS Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.